Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CHD5 |
| Gene Name: | CHD5 |
| Protein Full Name: | Chromodomain-helicase-DNA-binding protein 5 |
| Alias: | ATP-dependent helicase CHD5; CHD5; Chromodomain helicase-DNA-binding 5; EC 3.6.1.- |
| Mass (Da): | 223050 |
| Number AA: | 1954 |
| UniProt ID: | Q8TDI0 |
| Locus ID: | 26038 |
| COSMIC ID: | CHD5 |
| Gene location on chromosome: | 1p36.31 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19901 |
| Percent of cancer specimens with mutations: | 0.07 |
| Gene undergoes hypermethylation: | Yes in neuroblastoma, colon, gastric, breast |
| Normal role description: | CHD family proteins are thought to play a role in chromatin remodeling. CHD5 is most homologous to CHD3 and CHD4, which participate in the formation of a Nucleosome Remodeling and Deacetylation (NuRD) complex, in association with other proteins. This complex is generally thought to repress transcription of genes that are necessary for terminal differentiation. Empirically, methylation of the CHD5 gene has been demonstrated in numerous cancer systems supporting the role as TSP. |